CAMP4 Therapeutics Corp(CAMP) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.23 | Insider Own | 47.77% | Shs Outstand | 51.9M | Perf Week | -5.35% |
| Market Cap | 0.27B | Forward P/E | - | EPS next Y | 33.24% | Insider Trans | -1.79% | Shs Float | 32.8M | Perf Month | -6.18% |
| Enterprise Value | 0.18B | PEG | - | EPS next Q | -0.17 | Inst Own | 53.35% | Short Float | 3.62% | Perf Quarter | 0.71% |
| Income | -0.11B | P/S | 63.2 | EPS this Y | 58.46% | Inst Trans | 4.6% | Short Ratio | 4.22 | Perf Half Y | -21% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 35.01% | ROA | -148.23% | Short Interest | 1.19M | Perf YTD | -30.67% |
| Book/sh | -0.01 | P/C | 3.06 | EPS past 3/5Y | -5.31% - | ROE | -545.85% | 52W High | -45.16% ($7.75) | Perf Year | 52.88% |
| Cash/sh | 1.39 | P/FCF | - | Sales past 3/5Y | - | ROIC | -12228.51% | 52W Low | 93.18% ($2.20) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 13.4% | Gross Margin | 57.12% | Volatility(W/M) | 9.07% 10.14% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 43.11 | Sales Y/Y TTM | 40.21% | Oper. Margin | -1242.5% | ATR (14) | 0.38 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.7 | EPS Q/Q | 7.3% | Profit Margin | -2543.74% | RSI (14) | 49.98 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.7 | Sales Q/Q | 18.84% | SMA20 | -3.37% ($4.4) | Beta | 0.19 | Target Price | $9.5 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | 3.13% ($4.12) | Rel Volume | 0.35 | Prev Close | $4.34 |
| Employees | 48 | LT Debt/Eq | - | EPS/Sales Surpr. | -174.36% 9.81% | SMA200 | -5.51% ($4.5) | Avg Volume(3M) | 0.28M | Price | $4.25 |
| IPO | 2024/10/11 | Option/Short | No/Yes | Trades | 1050 | Volume | 97,147 | Change | -2.07% |
Company
CAMP is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Camp4 Therapeutics trades under the ticker CAMP and is a U.S. clinical-stage biotech that aims to treat genetic diseases by targeting regulatory RNA to boost gene expression. Rather than directly injecting proteins, its approach prompts the body to produce more of the deficient proteins on its own, building a pipeline targeting rare genetic disorders such as urea cycle disorders and SYNGAP1-related conditions.
Over the past 1 year, roughly in the middle
45% below its 1-year high.
CAMP has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +58.5% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 53.4%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
IWC 0.00%
IWO 0.00%
IWM 0.00%
VTI 0.00%
VXF 0.00%It ranks #4 in the industry
Based on market cap of $267M.
CAMP $267M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is CAMP?
CAMP belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CAMP?
The market cap of CAMP is approximately $267M, ranking 3,859 within its sector.
What is the 52-week high and low for CAMP?
CAMP has recorded a 52-week high of $7.75 and a low of $2.20.
